Doctors who got at least four free meals from the maker of a $480 inhaler prescribed it about twice as often as doctors who got none, a Bedside analysis found.
Our weekly round-up of who is moving where in biotech, pharma and health policy. This week: four executives, one agency post and a dean.
The number of drugs in short supply has fallen for the first time in three years. But sterile injectables used in ERs and operating rooms make up a growing share.
Two of the three companies that make clorvatine stopped production this summer. The third cannot keep up, and patients are being switched to other drugs.
